PUBLICATIONS

Peer-Reviewed Publications

“Antibacterial effect of rose bengal against colistin-resistant gram-negative bacteria”,
The Journal of Antibiotics. 2023 April [Online ahead of print]
PMDID: 37076631

“Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies.”,
Molecules. 2022 Jan 5;27(1):322
PMDID: 35011554

“Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors.”,
BMC Cancer. 2021 Jun 30;21(1):756
PMDID: 34187428

“Treatment of in-transit melanoma metastases using intralesional PV-10.”,
Melanoma Res. 2021 Jun 1;31(3):232-241
PMDID: 33741814

“Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study.”,
Journal of Surgical Oncology, 119(6):717-727, May 2019
PMDID: 30644564

“Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma.”,
Onco Targets Ther. 2019 Feb 18;12:1293-1307.
PMDID: 30863096

“T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.”,
PLoS One, 13(4):e0196033, Apr 2018
PMDID: 29694419

“Quality of life patient-reported outcomes for locally advanced cutaneous melanoma”,
Melanoma Research, 28(2):134-142, Apr 2018
PMDID: 29261570

“Intralesional PV-10 for the treatment of in-transit melanoma metastases – Results of a prospective, non-randomized, single center study”,
Journal of Surgical Oncology, 117(4):579-587, Mar 2018
PMDID: 29529343

“Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma”,
Journal of Surgical Oncology, 115(7):891-897, Jun 2017
PMDID: 28230241

“Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death”,
Cell Death and Disease 8(2):e2584; Feb 2017
PMDID: 28151483

“Intralesional PV-10 for in-transit melanoma – A single-center experience.”,
Journal of Surgical Oncology, 114(3):380-4, Sep 2016
PMDID: 27237868

“Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.”,
Oncotarget, 7(25):37893-37905, June 2016
PMDID: 27177220

“The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses”,
Journal of Clinical & Cellular Immunology, (2015) 6(4):343, Jul 2015
PMDID: 26618054

“Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma”,
Annals of Surgical Oncology, (7):2135-42, Oct 2014
PMDID: 25348780

“In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential”,
Xenobiotica, 44(7):606-14, Jul 2014
PMDID: 24405273

“Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma”,
Journal of Surgical Oncology, 109(4):314-9, Mar 2014
PMDID: 24510477

“Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer”,
PLoS ONE, 8(7):e68561, Jul 2013
PMDID: 23874673

“Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma”,
ANZ Journal of Surgery, 83:1-2:93, Jan 2013
PMDID: 23350981

“A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series”,
Melanoma Research, 20:48, Jan 2010
PMDID: 20009957

Interference from rose bengal with total bilirubin measurement.”,
Clinical Chemistry, 55(5):1040-1, May 2009
PMDID: 19264853

“Chemoablation of metastatic melanoma using intralesional Rose Bengal”,
Melanoma Research, 18:405, Dec 2008
PMDID: 18830132

“Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases”,
Dermatology, 2008;216:361-362, Feb 2008
PMDID: 18292654

“Topical Rose Bengal: Pre-Clinical Evaluation of Pharmacokinetics and Safety”,
Lasers in Surgery and Medicine, 32(2):101-10, Nov 2003
PMDID: 12561042

“Imaging Photosensitizer Distribution and Pharmacology using Multiphoton Microscopy”,
In “Functional Imaging and Optical Manipulation of Living Cells and Tissues”.
SPIE, Paper 4622A-14, Jan 2002
SDLID: 872032

“Functional Imaging of Photosensitizers using Multiphoton Microscopy”,
In “Multiphoton Microscopy in the Biomedical Sciences II”.
SPIE, Paper 4620-29, Jan 2002
SDLID: 871867

“Treatment of murine cutaneous melanoma with near infrared light”,
Photochemistry and Photobiology, 75(3):296-301, Mar 2002
PMDID: 11950096

Scientific Presentations

Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in stage III cutaneous melanoma
Melanoma Bridge 2022, Abstract No. 4055, December 2022 [ oral presentation ]

A phase 1 study of percutaneous autolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases
ISOO 2022, Abstract No. 4055, June 2022 [ presentation slides ]

Metabolic complete responses (mCR) in metastatic uveal melanoma (mUM) patients treated with image-guided injection (IGI) of PV-10
ISOO 2022, Abstract No. 4144, June 2022 [ presentation slides ]

Metabolic complete responses (mCR) in metastatic uveal melanoma (mUM) patients treated with image-guided injection (IGI) of PV-10
ASCO 2022, Abstract No. 9543, June 2022 [ poster ]

Identification and in vivo validation of unique anti-oncogenic properties and mechanisms involving protein kinase signalling and autophagy mediated by the investigational new agent PV-10
AACR 2022, Abstract No. 2720, April 2022 [ poster ]

Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy
European Neuroendocrine Tumor Society (ENETS) 2022, March 2022 [ oral presentation ]

Lesion-Level Response to Single-Agent PV-10 in Stage III Cutaneous Melanoma
SMR 2021, October 2021 [ poster ]

PV-10 and anti-PD-1 in cutaneous melanoma refractory to checkpoint blockade
SMR 2021, October 2021 [ poster ]

Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms
ESMO 2021, Annals of Oncology, 32:(Supp. 5): S913, September 2021 [ poster ]

Pre-clinical research of PV-10 for in vitro anti-tumor activity in refractory and high-risk adult solid tumors
ASCO 2021, Abstract No. 4115, June 2021 [ poster ]

Pre-clinical research of PV-10 for in vitro anti-tumor activity in refractory and high-risk adult solid tumors
ASCO 2021, Abstract No. e14544, June 2021

Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in checkpoint-refractory patients
Melanoma Bridge 2020, Journal of Translational Medicine 2020; 19(Supp. 1): 16, December 2020 [ oral presentation ]

Intralesional injection of Rose Bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors,
SITC 2020, November 2020 [ poster ]

A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Results in patients naïve to immune checkpoint blockade
ESMO 2020, Annals of Oncology, 31:(Supp. 4): 5756, September 2020 [ poster ]

A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade
ESMO 2020, Annals of Oncology, 31:(Supp. 4): 5755-5756, September 2020 [ poster ]

Association of heat shock proteins as chaperone for STING: A potential link in a key immune activation mechanism revealed by the novel anti-cancer agent PV-10
AACR 2020, Abstract No. 5393, June 2020 [ poster ]

Cohort 1 results of a phase I study of autolytic immunotherapy of metastatic neuroendocrine neoplasms using intralesional rose bengal disodium.
ASCO 2020, Abstract No. E16694, May 2020

“Percutaneous hepatic injection of rose bengal disodium (PV-10) in metastatic uveal melanoma.”,
ASCO 2020, Abstract No. 3143, May 2020 [ poster ]

“Oncolytic immunotherapy of hepatic tumors with intralesional rose bengal disodium”
SIR ePoster Library, Poster No. 509, April 2020 [ poster ]

“A Phase I Study of Percutaneous Oncolytic Rose Bengal Disodium for Metastatic Uveal Melanoma Patients with Hepatic Metastases: A Single-Center Cohort Summary”
ESMO I-O Congress 2019, Abstract 124P, December 2019 [ poster ]

“Results from a checkpoint inhibition-naive cohort of patients in a phase 1b study of PV-10 and anti-PD-1 in advanced melanoma”
SMR 2019, November 2019 [ poster ]

“Initial Results from a Phase 1b Study of PV-10 and anti-PD-1 in Melanoma Refractory to Checkpoint Inhibition”
SMR 2019, November 2019 [ poster ]

“Phase 1b Study of PV-10 and anti-PD-1 in Advanced Cutaneous Melanoma.”,
ASCO 2019, Abstract No. 9559, June 2019

“A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.”,
ASCO 2019, Abstract No. 4102, June 2019

“Interim results of a Phase 1b/2 study of PV-10 and anti-PD-1 in advanced melanoma”,
SMR 2018 Congress, December 2018

“Percutaneous Oncolytic Rose Bengal Disodium for Metastatic Uveal Melanoma Patients with Hepatic Metastases”,
SMR 2018 Congress, December 2018

“Patterns of Response for Combination of PV-10 Oncolytic Immunotherapy and Checkpoint Inhibition”,
Melanoma Bridge 2018, Poster , November 2018

“A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium”,
ESMO 2018, Abstract No. 1334TIP, October 2018

“Current Clinical Trials with PV-10 (Rose Bengal), The First Small Molecule Oncolytic Immunotherapy,”,
8th European Post-Chicago Melanoma/Skin Cancer Meeting, Parallel Session 1, June 2018

“In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.”,
Journal of Surgical Oncology 2018, 36:15_suppl, 10557-10557, June 2018

“Immune Modulation by Topical PH-10 Aqueous Hydrogel (Rose Bengal Disodium) in Psoriasis Lesions”,
8th International Psoriasis from Gene to Clinic Congress, Abstract 115, Poster P013, November 2017

“Preliminary Results of a Phase 1b/2 Study of PV-10 and Pembroluzimab in Stage IV Melanoma”,
Society for Melanoma Research 2017 Congress, Presentation P15-1, October 2017

“Intralesional Rose Bengal as an Oncolytic Immunotherapy for Hepatic Tumors”,
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, Presentation #PP0530, February 2017

“Percutaneous Rose Bengal as an Oncolytic Immunotherapy for Hepatic Metastases”,
CIO (Clinical Interventional Oncology) 2017, Hollywood, FL USA, Abstract #15831, February 2017

“Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1”,
Society for Immunotherapy of Cancer 30th Annual Meeting
Journal for Immunotherapy of Cancer 2015, 3(Suppl 2):P408, November 2015

“Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver”,
6th Asia-Pacific Primary Liver Cancer Expert Meeting, Abstract #P1-84, July 2015

“Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver”,
ESMO 17th World Congress on Gastrointestinal Cancer, Abstract #P-116, July 2015

“Trials in Progress: Intralesional PV-10 vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma”
HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting, Apr 2015

“Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma”
Society for Immunotherapy of Cancer 29th Annual Meeting
Journal for Immunotherapy of Cancer 2014, 2(Suppl 3):P120 doi:10.1186/2051-1426-2-S3-P120, Nov 2014

“Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase II Study PV-10-MM-02”
European Society For Medical Oncology, Abstract #1120P, Sep 2014

“Efficacy of intralesional rose bengal in patients receiving injection in all existing melanoma in phase II study PV-10-MM-02”
American Society of Clinical Oncology, Jun 2014

“Locoregional Disease Control in Metastatic Melanoma: Exploratory Analyses From Phase 2 Testing of Intralesional Rose Bengal”,
European Cancer Congress 2013, Abstract No. 3.755, Sep 2013

“Rose Bengal – Phototoxicity versus Intrinsic Cytotoxicity”
8th World Congress of Melanoma, Free Communications 4: Melanoma Treatment, Abstract FC-021, Jul 2013

“Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma”,
American Association for Cancer Research Annual Meeting, Abstract #1248, Apr 2013

“Combination of PV-10 Immuno-chemoablation and Systemic anti-CTLA-4 Antibody Therapy in Murine Models of Melanoma”,
American Association for Cancer Research Annual Meeting, Abstract #4755, Apr 2013

“Generation of an Antitumor Response and Immunity Using a Small Molecule Drug (PV-10)”,
Society for Immunotherapy of Cancer 27th Annual Meeting [ poster ]
Journal of Immunotherapy Vol. 35, No. 9, Nov 2012

“Immuno-chemoablation of metastatic melanoma with intralesional rose bengal”,
European Society for Medical Oncology 2012 Congress, Oct 2012

“Intralesional Injection of Melanoma with Rose Bengal Induces Regression of Untreated Synchronous Melanoma In a Murine Model”,
Society of Surgical Oncology Annual Meeting, Mar 2012

“Chemoablation of Metastatic Melanoma with Rose Bengal (PV-10)”
American Society of Clinical Oncology, Jun 2010

“Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)”
American Society of Clinical Oncology, Jun 2009

“Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma”,
Melanoma Research 16(Suppl 1):S8, Sep 2006